

comprehensive Multi-Year Planning (cMYP)

A Tool and User Guide for cMYP Costing and Financing

Update 2014



comprehensive Multi-Year Planning (cMYP)

A Tool and User Guide for cMYP Costing and Financing

Update 2014



**The Department of Immunization, Vaccines and Biologicals
thanks the donors whose unspecified financial support
has made the production of this document possible.**

This document was produced by the
Expanded Programme on Immunization
of the Department of Immunization, Vaccines and Biologicals

Ordering code: WHO/IVB/14.06
Printed: April 2014

This publication revises the original publication
(WHO/IVB/06.15)
published in December 2006

This publication is available on the Internet at:
www.who.int/vaccines-documents/

**Copies of this document as well as additional materials on
immunization, vaccines and biologicals may be requested from:**

World Health Organization
Department of Immunization, Vaccines and Biologicals
CH-1211 Geneva 27, Switzerland
• Fax: + 41 22 791 4227 • Email: vaccines@who.int •

© World Health Organization 2014

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

Printed by the WHO Document Production Services, Geneva, Switzerland

Contents

<i>Abbreviations and acronyms</i>	<i>v</i>
<i>Acknowledgments</i>	<i>vii</i>
<i>Introduction</i>	<i>ix</i>
1. Strategic planning for immunization with costing	1
1.1 <i>A revised approach to planning for immunization</i>	1
1.2 <i>Why cost a cMYP?</i>	2
1.3 <i>What are the costing linkages in the cMYP guidelines?</i>	2
1.4 <i>What are the cMYP linkages with broader health sector costing exercises?</i>	4
2. Overview of the cMYP Costing and Financing Tool	6
2.1 <i>Description of the worksheets in the cMYP Tool</i>	6
2.2 <i>Can the cMYP Tool be used in a decentralized setting?</i>	10
2.3 <i>Can the cMYP Tool be damaged?</i>	11
2.4 <i>What is the cMYP Tool not designed to do?</i>	11
2.5 <i>Where to send feedback and seek technical support</i>	12
3. Some principles and suggestions on procedure	13
4. Important concepts, methodologies and terms	16
4.1 <i>What to cost in a cMYP</i>	16
4.2 <i>What is the difference between a cost and a resource requirement?</i>	19
4.3 <i>What are the basic costing methodologies used?</i>	20
4.4 <i>What are some methodological differences and limitations?</i>	23
5. Using the cMYP Costing and Financing Tool	25
5.1 <i>Overview of the Data Entry worksheet</i>	25
5.2 <i>Review of each data table contained in the Data Entry worksheet</i>	31
5.3 <i>Costing results and tables</i>	63
5.4 <i>Overview of the financing and financing projections worksheets</i>	64
5.5 <i>Steps to complete the Financing worksheet</i>	66
5.6 <i>Steps to complete the Co-financing worksheet</i>	69
6. Analysis of results	71
6.1 <i>Analysis of past costing and financing (baseline)</i>	72
6.2 <i>Analysis of future resource requirements, financing and gaps</i>	74
6.3: <i>Analysis of immunization strategies</i>	79
6.4: <i>Sustainability analysis</i>	81
6.5 <i>Dashboard</i>	83

7. Scenario building	84
7.1 <i>Types of Scenarios.....</i>	<i>84</i>
7.2 <i>Using the cMYP Tool for scenario building.....</i>	<i>85</i>
8. Annual monitoring using the cMYP Costing and Financing Tool.....	87
8.1 <i>Annual planning and financial resources</i>	<i>87</i>
8.2 <i>Review of key assumptions on the costing</i>	<i>88</i>
8.3 <i>Financial management and trends on immunization financing.....</i>	<i>88</i>
8.4 <i>Reporting requirements.....</i>	<i>89</i>
9. Other uses of the cMYP Costing and Financing Tool information	90
10. Linkages to other costing tools	91
10.1 <i>WHO Vaccine Forecasting Tool.....</i>	<i>91</i>
10.2 <i>WHO–UNICEF Joint Reporting Form</i>	<i>91</i>
10.3 <i>WHO Cervical Cancer Prevention and Control Costing Tool (C4P)</i>	<i>91</i>
Annex I: Summary table of data needs and sources.....	92
Annex II: Glossary of important cMYP costing terms	99

Abbreviations and acronyms

AD	auto-disable syringe
APR	annual progress report
BCG	bacille Calmette-Guérin (tuberculosis vaccine)
CBAW	childbearing age women
CEA	cost-effectiveness analysis
cMYP	comprehensive Multi-Year Plan (for immunization)
cMYP Tool	cMYP Costing and Financing Tool
DFID	Department for International Development (United Kingdom)
DTP	diphtheria-tetanus-pertussis (vaccine)
EPI	Expanded Programme on Immunization
FIC	fully immunized children
GAVI	the GAVI Alliance (formerly the Global Alliance for Vaccines and Immunisation)
GDP	gross domestic product
GHE	government health expenditure
GIVS	Global Immunization Vision and Strategy
GVAP	Global Vaccine Action Plan
HepB	hepatitis B (vaccine)
Hib	Haemophilus Influenzae type B (vaccine)
HIPC	highly indebted poor country
ICC	inter-agency coordinating committee
IEC	information, education and communication
IMF	International Monetary Fund
IMR	infant mortality rate
JICA	Japan International Cooperation Agency
JRF	WHO–UNICEF Joint Reporting Form
LCU	local currency units

MDG	Millennium Development Goal
MDRI	multilateral debt relief initiative
MoF	ministry of finance
MoH	ministry of health
MTEF	medium-term expenditure framework
MYP	multi-year plan (for immunization)
NHA	national health accounts
NIP	national immunization programme
OPV	oral polio vaccine
PRSP	poverty reduction strategy papers
SIA	supplemental immunization activities (campaigns)
SWAp	sector-wide approach
TB	tuberculosis
THE	total health expenditure
TT	tetanus toxoid (vaccine)
U1P	under one population
ULY	useful life years
UNICEF	United Nations Children's Fund
US\$	United States dollars
USAID	United States Agency for International Development
WHO	World Health Organization

Acknowledgments

This document has been revised by the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF), with the support of other immunization partners, to reflect the updated version of the cMYP Costing and Financing Tool. The revised document replaces the previous publication, Immunization costing & financing: a tool and user guide for comprehensive Multi-Year Planning (cMYP) (2006, WHO/IVB/06.15).

The original contributors to the document are partners of the GAVI Alliance: the Bill & Melinda Gates Foundation, the Centre for Global Development, the Children's Vaccine Programme at PATH, UNICEF, the United States Agency for International Development (USAID), the World Bank and WHO.

The revisions were made by Claudio Politi, Michael Hinsch (WHO Headquarters) and Ann Levin, independent consultant. We would like to express our gratitude to Jean-Bernard Le Gargasson (Agence de Médecine Préventive), William Meaney and Viktor Galayda (independent consultants) who reviewed the document. Our special thanks go to the numerous national EPI Managers and colleagues from WHO and UNICEF regional and country offices and immunization partners who contributed to the review.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27801

